Mencari ubat atas namanya

Adalat CC dan CHF / AMI

Hasil ujian interaksi ubat Adalat CC dan penyakit CHF / AMI untuk kontraindikasi dan kesan sampingan dengan penggunaan bersama.

Hasil pemeriksaan:

Adalat CC <> CHF / AMI

Relevan: 23.07.2019 Pengulas: MD P.M. Shkutko, in

Kontraindikasi atau kesan sampingan yang boleh membahayakan atau meningkatkan kesan negatif apabila menggunakan ubat dengan penyakit ditemui saat pemeriksaan interaksi mengikut sumber yang bereputasi - Drugs.com, RXList.com, Webmd.com, MedScape.com.

Pengguna:

Kalsium penghalang saluran (CCBs) mungkin telah berubah derajat negatif inotropic kesan. Kegagalan jantung (USD), semakin teruk CAD, dan paru-paru telah berlaku dalam beberapa pasien yang diobati dengan CCB, terutamanya verapamil. Beberapa CCBs juga telah menyebabkan ringan untuk sederhana pinggiran edema kerana setempat vasodilatasi bergantung arteriol dan saluran darah kecil, yang bisa menjadi bingung dengan kesan meningkatkan kiri ventrikular disfungsi. Walaupun beberapa CCBs telah digunakan dalam rawatan CAD, terapi dengan CCBs perlu diberikan berhati-hati pesakit dengan teruk kiri ventrikular disfungsi (contohnya, pecahan pelemparan < 30%) atau sederhana untuk gejala yang teruk daripada kegagalan jantung dan pada pasien dengan mana-mana tahap ventrikular disfungsi jika mereka menerima beta-adrenergic blocker. Begitu juga, awas dinasihatkan pada pasien dengan sakit jantung dan paru-paru kesesakan didokumentasikan oleh X-ray di kemasukan, sejak berkaitan kegagalan jantung mungkin akut bertambah buruk oleh pentadbiran CCB.

Sumber

Batlouni M, Armaganijan D, Ghorayeb N, Magliano MF "Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients." J Cardiovasc Pharmacol 19 (1992): s53-7
"Product Information. Procardia (nifedipine)." Pfizer US Pharmaceuticals, New York, NY.
Fagan TC, Haggert BE, Liss C "Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension." Clin Ther 16 (1994): 634-46
Sleight P "Calcium antagonists during and after myocardial infarction." Drugs 51 (1996): 216-25
Brogden RN, Sorkin EM "Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension." Drugs 49 (1995): 618-49
Batra AK, Segall PH, Ahmed T "Pulmonary edema with nifedipine in primary pulmonary hypertension." Respiration 47 (1985): 161-3
Elkayam U "Calcium channel blockers in heart failure." Cardiology 89 (1998): 38-46
Prigogine T, Waterlot Y, Gottignies P, et al "Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension." Chest 100 (1991): 563-4
Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995): 1-7
"Product Information. Norvasc (amlodipine)." Pfizer US Pharmaceuticals, New York, NY.
Lorimer AR, Pringle SD "The safety of felodipine." J Cardiovasc Pharmacol 15 (1990): s85-9
Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986): 133-6
Yedinak KC, Lopez LM "Felodipine: a new dihydropyridine calcium-channel antagonist." DICP 25 (1991): 1193-206
Taylor SH, Frais MA, Lee P, Verma SP, Jackson N, Reynolds G, Silke B "A study of the long-term efficacy and tolerability of oral nicardipine in hypertensive patients." Br J Clin Pharmacol 20 (1985): s139-42
Sundstedt CD, Ruegg PC, Keller A, Waite R "A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension." Am J Med 86 (1989): 98-102
"Product Information. Sular (nisoldipine)." Zeneca Pharmaceuticals, Wilmington, DE.
Blecker D "Antihypertensive therapy with isradipine in patients with special safety concerns." Angiology 45 (1994): 997-1008
Johnson BF, Eisner GM, Mcmahon FG, Jain AK, Rudd P, Sowers JR "A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension." J Clin Pharmacol 35 (1995): 484-92
Dubois C, Blanchard D "Efficacy and safety of nicardipine in 29,104 patients with hypertension." Clin Ther 11 (1989): 452-60
"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc, Palo Alto, CA.
Gillmer DJ, Kark P "Pulmonary oedema precipitated by nifedipine." Br Med J 280 (1980): 1420-1
Walton T, Symes LR "Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension." Clin Pharm 12 (1993): 261-75
"Product Information. DynaCirc (isradipine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
Scheidt S, LeWinter MM, Hermanovich J, Venkataraman K, Freedman D "Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial." Am J Cardiol 58 (1986): 715-21
Schaefer RM, Aldons PM, Burgess ED, Tilvis R, Singh GP, Rehn L, Morgan TO "Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: A randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events." Int J Clin Pract 52 (1998): 381
"Product Information. Plendil (felodipine)." Merck & Co, Inc, West Point, PA.
Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999): 1447-57
Ruegg PC, Nelson DJ "Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris." Am J Med 86 (1989): 70-4
"Product Information. Nimotop (nimodipine)." Bayer, West Haven, CT.